HANSOH PHARMACEUTICAL GROUP COMPANY LIMITED

News Hansoh Pharmaceutical Group Company Limited

Equities

3692

KYG549581067

Pharmaceuticals

Delayed Hong Kong S.E. Other stock markets 04:43:54 18/07/2025 BST			5-day change	1st Jan Change
34.75 ^HKD	+0.72%		+10.32%	+101.10%

07-17	Nomura Adjusts Hansoh Pharmaceutical Group's Price Target to HK$31.82 From HK$25.64, Keeps at Neutral	MT
06-04	Hansoh Pharmaceutical Group Company Limited Announces Approval of Aumolertinib Mesilate Tablets by the Medicines and Healthcare Products Regulatory Agency for Marketing	CI

Nomura Adjusts Hansoh Pharmaceutical Group's Price Target to HK$31.82 From HK$25.64, Keeps at Neutral	07-17	MT
Hansoh Pharma \| Aumolertinib: Approved by UK’s MHRA for the Treatment of NSCLC — Marking the First Overseas Launch of China-Developed EGFR-TKI	06-05	PU
Hansoh Pharmaceutical Group Company Limited Announces Approval of Aumolertinib Mesilate Tablets by the Medicines and Healthcare Products Regulatory Agency for Marketing	06-04	CI
Hansoh Pharmaceutical Says Aumolertinib Mesilate Tablets Approved By MHRA For Marketing	06-04	RE
Hansoh Pharma's Lung Cancer Drug Aumseqa Wins UK Marketing Approval	06-04	MT
Nomura Adjusts Hansoh Pharmaceutical Group's Price Target to HK$25.64 From HK$19.86, Keeps at Neutral	06-03	MT
Hansoh Pharma Licenses GLP-1 Drug to Nasdaq-listed Regeneron in $2 Billion Deal	06-03	MT
Regeneron's weight-loss drug helps patients on Wegovy preserve muscle	06-02	RE
Hansoh Pharmaceutical Says Units Entered Into A License Agreement With Regeneron Pharmaceuticals	06-02	RE
Regeneron Signs Licensing Agreement for Chinese Weight Loss Drug	06-02	DJ
Hansoh Pharmaceutical : PHARMA GRANTS REGENERON AN EXCLUSIVE LICENSE RIGHTS TO ITS INVESTIGATIONAL DUAL GLP-1/GIP RECEPTOR AGONIST HS-20094	06-02	PU
Hansoh Pharmaceutical : PHARMA ANNOUNCES THE THIRD BIOLOGICS LICENSE APPLICATION OF XINYUE(INEBILIZUMAB INJECTION) ACCEPTED BY NMPA FOR THE TREATMENT OF GENERALIZED MYASTHENIA GRAVIS IN ADULT PATIENTS	05-31	PU
Hansoh Pharmaceutical Group Company Limited Announces the Third Biologics License Application of Xin Yue (Inebilizumab Injection) Has Been Accepted by the National Medical Products Administration	05-30	CI
Hansoh Pharmaceutical Says Third Biologics License Application Of Xinyue (Inebilizumab Injection) Accepted By NMPA	05-30	RE
Chinese Regulator Accepts Hansoh Pharmaceutical's License Application for Generalized Myasthenia Gravis Drug	05-30	MT
Hansoh Pharmaceutical Group Company Limited Obtains Clinical Trial Approval Issued by the National Medical Products Administration	05-29	CI
Hansoh Pharmaceutical Group Company Limited Obtains Clinical Trial Approval Issued by the National Medical Products Administration	05-29	CI
Hansoh Pharmaceutical Group Company Limited Obtains Clinical Trial Approval Issued by the National Medical Products Administration	05-29	CI
Hansoh Pharmaceutical Says Clinical Trial Approval For HS-10542 Capsules Issued By NMPA	05-29	RE
Hansoh Pharmaceutical Gets China Nod for Clinical Trial of Three Drugs	05-29	MT
Hansoh Pharmaceutical Says Clinical Trial Approval For HS-20118 Tablets Issued By NMPA	05-29	RE
Hansoh Pharmaceutical Says Clinical Trial Approval For HS-10510 Tablets Issued By NMPA	05-29	RE
Weight-loss drug developers line up to tap lucrative market as competition heats up	05-16	RE
New purchases in the Asia Investor portfolio	05-14
Hansoh Pharmaceutical Gets China Registration Nod for New Indication of Lung Cancer Drug	05-12	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Hansoh Pharmaceutical Group Company Limited : Regulator grants breakthrough-therapy status to lung cancer drug

December 03, 2024 at 05:32 pm